Paper Details

  1. Home
  2. Paper Details

Comparison of Adverse Events Occurred During Administration of Dipeptidyl Peptidase-4 Inhibitor in Patients with Diabetes Using FDA Adverse Event Reporting System.

Author: OguraToru, ShiraishiChihiro

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study examines the adverse events associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, a class of drugs used for diabetes treatment, using FDA Adverse Event Reporting System (FAERS) data. The study aims to identify and compare the frequencies of known serious side effects among different DPP-4 inhibitors.
Paper Details　
Original Abstract of the Article :
Various dipeptidyl peptidase-4 (DPP-4) inhibitors have been approved for the treatment of diabetes. The frequencies of known serious side effects might differ among DPP-4 inhibitors, therefore a large sample size is needed to study them in prospective clinical trials. We examined the adverse events ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40261-022-01242-7

データ提供：米国国立医学図書館（NLM）

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Comprehensive Analysis of Adverse Events

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of drugs used to treat diabetes. While these drugs are generally safe and effective, they can have adverse effects. This study examines a large dataset from the FDA Adverse Event Reporting System (FAERS) to assess the frequency and types of adverse events associated with DPP-4 inhibitors in patients with diabetes. The authors aim to provide a comprehensive overview of the potential risks and benefits of these medications.

Understanding Adverse Events: Navigating the Desert of Side Effects

This study provides a comprehensive analysis of adverse events associated with DPP-4 inhibitors. It's like mapping the desert of potential side effects, identifying the hazards and offering insights into the risks and benefits of these medications. This information is crucial for clinicians and patients to make informed decisions about treatment and minimize the potential for adverse effects.

Making Informed Decisions: A Journey Through the Desert of Medications

Navigating the world of medications can be like traversing a vast desert, with different paths leading to different destinations. This study provides a roadmap for understanding the potential side effects of DPP-4 inhibitors, helping both patients and clinicians make informed decisions about treatment strategies. By weighing the risks and benefits, we can choose the path that leads to the most effective and safe treatment outcomes.

Dr.Camel's Conclusion

This study serves as a valuable resource for understanding the potential adverse events associated with DPP-4 inhibitors. It's like having a seasoned guide who can help you navigate the complexities of medication and make informed choices for your health. The research emphasizes the importance of open communication between patients and clinicians to ensure safe and effective treatment approaches.
Date :
  1. Date Completed 2023-02-08
  2. Date Revised 2023-02-08
Further Info :

Pubmed ID

36637688

DOI: Digital Object Identifier

10.1007/s40261-022-01242-7

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.